Skip to main content
Figure 1 | BMC Neurology

Figure 1

From: The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial

Figure 1

Distribution of patients by ADAS-Cog and patient/caregiver-GAS response after 6 months of donepezil therapy. Patient responses on the ADAS-Cog at 6 months were categorized as improved (change from baseline ≤ -4 points), no change (-3 to 3) or worsened (≥ 4) and crossed against patient/caregiver-GAS (PGAS) improvement (change from baseline ≥ 6), no change (-5 to 5) or worsening (≤ -5) for total PGAS goals (A) and PGAS cognition goals (B). An asterisk (*) denotes agreement between measures – overall 42% for total PGAS and 47% for PGAS-cognition.

Back to article page